Soluble Guanylate Cyclase Stimulators and Activators As Potential Antihypertensive Drugs

Overview

Journal Hypertens Res

Date 2025 Jan 20

PMID 39833553

Authors

Masashi Tawa

Keisuke Nakagawa

Mamoru Ohkita

Affiliations

Soon will be listed here.

Abstract

Poor blood pressure control in treated patients with hypertension is an important topic in the field of hypertension, and an unmet need for new therapeutic drugs remains. Soluble guanylate cyclase (sGC), a key signal transduction enzyme responsible for vasodilation, has attracted increasing interest as a therapeutic target in various cardiovascular diseases. Two different sGC agonists, sGC stimulators and activators, can increase its enzymatic activity in reduced and oxidized/apo forms, respectively. With some sGC agonists being already in clinical use, drugs in this category are expected to become new therapeutic agents for various conditions, including hypertension. In this review, we summarize the current knowledge on the antihypertensive effects of sGC agonists in various preclinical studies involving animal models of spontaneous hypertension, salt-sensitive hypertension, nitric oxide-deficient hypertension, renin-angiotensin-aldosterone system-dependent hypertension, malignant hypertension, metabolic syndrome, renoprival hypertension, renovascular hypertension, drug-induced hypertension, pregnancy hypertension, and treatment-resistant hypertension. Our compilation provides a comprehensive rationale for advancing the clinical development of sGC agonists for the treatment of hypertension.

References

Cohuet G, Struijker-Boudier H . Mechanisms of target organ damage caused by hypertension: therapeutic potential. Pharmacol Ther. 2005; 111(1):81-98. DOI: 10.1016/j.pharmthera.2005.09.002. View

Kanbay M, Copur S, Tanriover C, Ucku D, Laffin L . Future treatments in hypertension: Can we meet the unmet needs of patients?. Eur J Intern Med. 2023; 115:18-28. DOI: 10.1016/j.ejim.2023.06.008. View

Lucas K, Pitari G, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S . Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 2000; 52(3):375-414. View

Schulz E, Gori T, Munzel T . Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res. 2011; 34(6):665-73. DOI: 10.1038/hr.2011.39. View

Macallister R, Vallance P . Nitric oxide in essential and renal hypertension. J Am Soc Nephrol. 1994; 5(4):1057-65. DOI: 10.1681/ASN.V541057. View

Toda N, Arakawa K . Salt-induced hemodynamic regulation mediated by nitric oxide. J Hypertens. 2010; 29(3):415-24. DOI: 10.1097/HJH.0b013e328341d19e. View

Rajapakse N, Head G, Kaye D . Say NO to Obesity-Related Hypertension: Role of the L-Arginine-Nitric Oxide Pathway. Hypertension. 2016; 67(5):813-9. DOI: 10.1161/HYPERTENSIONAHA.116.06778. View

Rajapakse N, Giam B, Kuruppu S, Head G, Kaye D . Impaired l-arginine-nitric oxide pathway contributes to the pathogenesis of resistant hypertension. Clin Sci (Lond). 2019; 133(20):2061-2067. DOI: 10.1042/CS20190851. View

Lundberg J, Gladwin M, Weitzberg E . Strategies to increase nitric oxide signalling in cardiovascular disease. Nat Rev Drug Discov. 2015; 14(9):623-41. DOI: 10.1038/nrd4623. View

10.

Evgenov O, Pacher P, Schmidt P, Hasko G, Schmidt H, Stasch J . NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006; 5(9):755-68. PMC: 2225477. DOI: 10.1038/nrd2038. View

11.

Tawa M, Okamura T . Factors influencing the soluble guanylate cyclase heme redox state in blood vessels. Vascul Pharmacol. 2022; 145:107023. DOI: 10.1016/j.vph.2022.107023. View

12.

Sandner P, Zimmer D, Milne G, Follmann M, Hobbs A, Stasch J . Soluble Guanylate Cyclase Stimulators and Activators. Handb Exp Pharmacol. 2019; 264:355-394. DOI: 10.1007/164_2018_197. View

13.

Sandner P, Follmann M, Becker-Pelster E, Hahn M, Meier C, Freitas C . Soluble GC stimulators and activators: Past, present and future. Br J Pharmacol. 2021; 181(21):4130-4151. DOI: 10.1111/bph.15698. View

14.

Joshi C, Martin D, Fox J, Mendelev N, Brown T, Tulis D . The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways. J Pharmacol Exp Ther. 2011; 339(2):394-402. PMC: 3199990. DOI: 10.1124/jpet.111.183400. View

15.

Holt A, Martin D, Shaver P, Adderley S, Stone J, Joshi C . Soluble guanylyl cyclase-activated cyclic GMP-dependent protein kinase inhibits arterial smooth muscle cell migration independent of VASP-serine 239 phosphorylation. Cell Signal. 2016; 28(9):1364-1379. PMC: 4947434. DOI: 10.1016/j.cellsig.2016.06.012. View

16.

Hung Y, Liu Y, Wu B, Yeh J, Hsu J . Cinaciguat Prevents Postnatal Closure of Ductus Arteriosus by Vasodilation and Anti-remodeling in Neonatal Rats. Front Physiol. 2021; 12:661171. PMC: 8358454. DOI: 10.3389/fphys.2021.661171. View

17.

Jama H, R Muralitharan R, Xu C, ODonnell J, Bertagnolli M, Broughton B . Rodent models of hypertension. Br J Pharmacol. 2021; 179(5):918-937. DOI: 10.1111/bph.15650. View

18.

Mulsch A, Bauersachs J, Schafer A, Stasch J, Kast R, Busse R . Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol. 1997; 120(4):681-9. PMC: 1564520. DOI: 10.1038/sj.bjp.0700982. View

19.

Ruetten H, Zabel U, Linz W, Schmidt H . Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res. 1999; 85(6):534-41. DOI: 10.1161/01.res.85.6.534. View

20.

Ndisang J, Wu L, Zhao W, Wang R . Induction of heme oxygenase-1 and stimulation of cGMP production by hemin in aortic tissues from hypertensive rats. Blood. 2002; 101(10):3893-900. DOI: 10.1182/blood-2002-08-2608. View